Spruce (SPRB) news

Quebecor Inc.: National Bank of Canada cuts target price to C$71 from C$74

National Bank of Canada has revised its target price for Quebecor Inc. (TSE:QBR.B) to C$71 from C$74, reflecting a slight downward adjustment in its valuation outlook for the company. The move suggests a recalibration of expectations, potentially influenced by recent market dynamics or internal…

Spruce Biosciences: Ta-ert EAP and transform study expected to initiate in Q4 2026

Spruce Biosciences, Inc. (Nasdaq: SPRB) has confirmed that its planned Biologics License Application (BLA) for tralesinidase alfa enzyme replacement therapy (TA-ERT) remains on track for submission in the fourth quarter of 2026, following positive pre-BLA meetings with the FDA . The company has…

Spruce: confirms BLA submission for TA-ERT on track for 4Q

Spruce Biosciences, Inc. (Nasdaq: SPRB) has confirmed that its Biologics License Application (BLA) submission for tralesinidase alfa enzyme replacement therapy (TA-ERT) remains on track for the fourth quarter of 2026. The company recently concluded two Type B meetings with the U.S. Food and Drug…

Spruce Biosciences: positive pre-BLA meetings with FDA

Spruce Biosciences: FDA and Spruce aligned on content and format of planned BLA